首页> 外文期刊>Circulation journal >'Just make it lower' is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con).
【24h】

'Just make it lower' is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con).

机译:在日本患者中,使用他汀类药物进行降脂治疗的另一种策略是“降低胆固醇”:LDL-胆固醇:越低越好;亚洲人是真的吗? (骗局)。

获取原文
获取原文并翻译 | 示例
           

摘要

It is well known that statins improve the prognosis of cardiovascular diseases (CVD). Recent randomized control trials (RCTs) of statins conducted in Western countries revealed greater avoidance of cardiovascular events if low-density-lipoprotein cholesterol (LDL-C) reached lower levels. However, it is obvious that this evidence cannot be unconditionally extrapolated to Asians because there are great differences between Japanese and Caucasians in the absolute onset rate of CVD. Results of RCTs with Japanese for primary or secondary prevention of cardiovascular events indicate that we could benefit from statins with a relatively higher target LDL-C as compared with Western populations. In this situation, not only strong but also standard statins are still advantageous and the so-called pleiotropic effects of the drugs come to the fore. In this review, we first discuss differences in the absolute event rate in different populations, and then the lack of evidence for recommended LDL-C treatment targets, particularly in Japanese, although there is reliable evidence for reductions in plaque volume in coronary arteries from RCTs recently conducted in Japan with aggressive lipid-lowering therapy with strong statins. Finally, based on recent data, we propose a new concept regarding the secondary prevention of CVD for current Japanese populations.
机译:众所周知,他汀类药物可改善心血管疾病(CVD)的预后。最近在西方国家进行的他汀类药物随机对照试验(RCT)显示,如果低密度脂蛋白胆固醇(LDL-C)达到较低水平,则可以更好地避免心血管事件。但是,很明显,这一证据不能无条件地推导出亚洲人,因为日本人和高加索人之间在CVD的绝对发病率方面存在很大差异。与日本人进行心血管疾病一级或二级预防的RCT结果表明,与西方人群相比,我们可以从目标LDL-C相对较高的他汀类药物中获益。在这种情况下,不仅强效他汀类药物还是标准他汀类药物仍然是有利的,并且药物的所谓多效性效应日益突出。在这篇综述中,我们首先讨论了不同人群中绝对事件发生率的差异,其次是缺乏推荐的LDL-C治疗目标的证据,特别是在日本人中,尽管有可靠的证据表明RCT减少了冠状动脉斑块体积最近在日本进行了强效他汀类药物的降脂治疗。最后,根据最新数据,我们提出了有关当前日本人群CVD二级预防的新概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号